Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Purdue Researcher's New 'Tool for the Organic Chemist Toolbox' Licensed to Sigma-Aldrich

Published: Friday, May 24, 2013
Last Updated: Friday, May 24, 2013
Bookmark and Share
U.S. patent for a safer, easier and "greener" method to incorporate fluorine into organic compounds has been licensed to a subsidiary of Sigma-Aldrich Corporation.

David A. Colby, a Purdue assistant professor of medicinal chemistry and organic chemistry, developed a chemical reagent that safely makes fluorine available during the creation of a new chemical compound. This reagent could provide drug manufacturers an improved method for using fluorine in the drug discovery process and enhance large-scale production of drugs for pharmaceutical manufacturers.

Aldrich Chemical Co. LLC has licensed the technology and will make the product available for sale through the Sigma-Aldrich catalog and website. Aldrich signed the license agreement with the Purdue Research Foundation and its Purdue Office of Technology Commercialization.

"Fluorine-carbon bonds are incredibly strong and are the secret to the strength of materials like Teflon and agricultural treatments that withstand the elements, and they also help pharmaceuticals hold up well inside our bodies," Colby said. "Fluorine has greatly advanced these industries, and now we have solved a key problem associated with using a commonly available starting material, fluoroform gas, an environmental hazard that is difficult to use in the laboratory. What we've done is create a new tool for the chemist's toolbox."

Fluoroform gas requires special handling and protection of the user and produces ozone-destroying fluorocarbons if released into the atmosphere. The reagent Colby developed is a stable solid that can be easily stored at room temperature, weighed and measured in the open air and requires no unusual protection measures. The reagent also has little waste and is made up of compounds that are safe for the environment. Once safely added to a solvent contained in the chemical processing equipment, the reagent releases fluoroform gas that is easily incorporated into the chemical process, he said.

Pharmaceutical companies have long recognized the beneficial effects of fluorine atoms in drug molecules because of their ability to improve such things as drug delivery, selectivity and efficacy. About 20 percent of all drugs on the market contain fluorine, including three of the current top-10 best-selling drugs including Lipitor® and Prevacid®.

"A chemist must have ways to manipulate properties in order to study the effectiveness of a drug," Colby said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Zika Virus Structure Revealed
Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.
Monday, April 04, 2016
Bird Flu Expert Working on Vaccine that Protects Against Multiple Strains
As the bird flu outbreak in China worsens, a Purdue University expert is working on vaccines that offer broader protection against multiple strains of the virus.
Friday, May 10, 2013
Discovery Points to New Approach to Fight Dengue Virus
Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, suggests new approach for designing vaccines against the aggressive mosquito-borne pathogen.
Monday, April 15, 2013
Researcher Taking Shot at Flu Vaccine That's More Effective, Easier to Make
In the midst of an unusually deadly flu season and armed with a vaccine that only offers partial protection, researcher is working on a flu vaccine that overcomes the need to predict which strains will hit each year.
Monday, February 11, 2013
Scientific News
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!